Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Apr 15 2023

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 2 pages · English

Summary by 6ix AI

Zydus Lifesciences Limited has issued a press release announcing that it received final approval from the USFDA for Isoproterenol Hydrochloride Injection. The injection is indicated for improving hemodynamic status in patients experiencing certain types of shock and for treating bronchospasm during anesthesia. The product will be manufactured at Zydus's facility in Jarod, India. This approval adds to Zydus's portfolio, which now includes a significant number of approvals since the filing process began.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases